TOPIC
 / company

Insilico Medicine

(英矽智能)

Related Topics:
Insilico Medicine
英矽智能
Insilico, based in Boston and Hong Kong, uses end-to-end generative artificial intelligence (AI) to identify novel targets and disease hypotheses and generative innovative drug candidates. Its Pharma.AI platform operates across biology, chemistry and clinical medicine to identify drug candidates.
The deal further validates Insilico’s AI-driven drug discovery platform, which the company claims can slash drug-development timelines to 12 to 18 months from the average of 4.5 years. Photo: Shutterstock
Biomedicine: Companies

Insilico signs US$888 million AI drug deal days after Hong Kong IPO

Multi-year partnership with France’s Servier will use Insilico’s AI platform to explore novel cancer drugs.

Banking & finance

The ‘biology winter’ thaws: why investors are buying Hong Kong’s biotech IPOs

Hong Kong economy

Editorial | Hong Kong’s IPO market rings in 2026 on a high note

Hong Kong stock market

Hong Kong stocks edge higher on last full trading day of year

Hang Seng Index edges higher as Chinese yuan surpasses 7 against US dollar for first time since May 2023.

People walk past Exchange Square in Central, home of Hong Kong’s bourse operator, on March 28, 2025. Photo: Matthew Miller
IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

IPO

Insilico Medicine leads 6 Hong Kong IPOs, capping banner fundraising year

Debutants raise total of US$899 million as exchange wraps up one of the most active months for IPOs since 2021.

Advertisement
Advertisement
Advertisement
IPO

Holiday rush: Hong Kong IPO market sparkles with busiest December in years

From biotech to AI, December’s listings – including at least 15 down the stretch – crown the city’s revival in equity fundraising.

Insilico Medicine says its listing could raise up to HK$2.3 billion. Photo: Shutterstock
Biomedicine: Companies

China’s drug innovators bank on AI to hasten discovery to commercial success

A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition.

videocam
Artificial intelligence

Biotech firm touts new AI drug discovery amid third Hong Kong IPO attempt

Insilico Medicine said results of a clinical trial in China showed positive results in treating idiopathic pulmonary fibrosis.

IPO

More Hong Kong IPO hopefuls emerge as sentiment draws investors

SAIC Mobility unveiled its plans on Friday; others like Mirxes, Insilico and CiDi revive their applications, according to exchange filings.

videocam
Exchange Square in Central. Photo: Jelly Tse
Hong Kong’s belt and road impact

How two Hong Kong firms’ innovative solutions enhance well-being in belt and road regions

Modern Dental Group and Insilico Medicine keen to use city’s unrivalled global connections to create a healthier world.

In partnership with:
Belt and Road Office
Hong Kong-based health technology firms, such as Modern Dental Group and Insilico Medicine, are leveraging the city’s strategic advantages to drive worldwide healthcare-related collaboration. Photo: Shutterstock
Artificial intelligence

Generative AI helps Hong Kong’s Insilico Medicine design potential new IBD drug

Using AI, Insilico took only 12 months from initiating the project to nominating the molecule for preclinical trials, instead of several years.

Science

Drug development can take over a decade. AI helped make a medicine in 18 months

Evidence that AI tools can slash years off early-stage analysis will ‘revolutionise drug discovery’, researchers say.

videocam
Banking & finance

Hong Kong’s Insilico sells cancer drug candidate in potential US$500 million deal

Stemline Therapeutics, a wholly-owned unit of Menarini Group, will make a US$12 million upfront payment to Insilico under the agreement, which will be followed by sales royalties worth up to ‘double digits’.

Hong Kong-based AI-driven company sells potential breast cancer drug in deal whose value could exceed US$500 million
Medicine

Exclusive | Hong Kong’s Insilico, Aramco to partner on sustainable fuels and materials

AI drug discovery unicorn Insilico Medicine is set to sign a deal with Saudi Arabia’s Aramco and a subsidiary during Hong Kong leader John Lee Ka-chiu’s official visit to the country.

videocam
Insilico opened a regional research centre in Abu Dhabi this month. The opening ceremony was attended by Alex Zhavoronkov, Insilico’s co-founder and CEO, Omar Al Olama, the UAE’s Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications, Ahmed Baghoum, the acting CEO of Masdar City, and Alex Aliper, Insilico’s co-founder and president. Photo: Handout
Medicine

Sanofi signs with Hong Kong biotech firm Insilico to spur AI drug discovery

French pharmaceutical giant Sanofi will collaborate with Hong Kong-based biotech firm Insilico Medicine in a deal worth up to US$1.2 billion to speed up the drug-discovery process using artificial intelligence.

videocam
Wellness

How AI is revolutionising drug industry by cutting research time

AI can save up to two years in pharmaceutical research and development time, says CEO of drug-development company Insilico Medicine, which is moving its headquarters to Hong Kong.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement